This time, it was Wei Kang that issued the announcement, stating that the company's new drug research and development has achieved a virtuous cycle and that it is not short of money for the time being.
Instead, the next goal is to spend more money, especially on research and development. Three Purities still lags significantly behind international pharmaceutical giants in this area. The short-term goal is to catch up, while the long-term goal is to strive to far surpass its peers.
At the same time, Sanqing Group's pharmaceutical business will absolutely not be listed on the stock exchange.
As soon as the news broke, netizens burst into laughter.
"President Wei is awesome, a man that capital can't get."
"I'm so happy to see capital suffer."
"The next goal is to spend more money to catch up with Pfizer, right? I'm laughing so hard I almost choked."
"That's exactly right. Pharmaceutical companies should serve the people and meet social needs. How can they be controlled by capitalists?"
"If we don't go public, we won't be controlled by capital, and we won't sell overpriced drugs. Now we can rest assured."
"Foreign pharmaceutical giants invest tens of billions of US dollars in R&D every year. I think President Wei's spending plan might be a bit difficult."
"No problem at all. Just give each person in the country 100 yuan, and you'll easily achieve your goal, hahaha."
"Haven't you all figured out what President Wei is trying to do? He's aiming to single-handedly revitalize the entire city. Kun City is about to boom, and housing prices are likely to skyrocket!"
"I could tell they were probably hiring again, hehe. I'm graduating soon, so I'm going to start sending out resumes."
"I envy the top student upstairs. If I could turn back time, I would have chosen biochemistry as my major too."
"Putting everything else aside, if Three Purities's R&D investment were as high Huawei's, it could support the entire domestic pharmaceutical industry."
"Yes, you don't know, the total R&D investment of all domestic pharmaceutical companies combined is less than that of a single foreign giant, and the R&D investment of foreign pharmaceutical giants is still less than that of Huawei. Huawei ranks third in the world in R&D investment."
"Hiss, this is terrifying! Is Three Purities going to become the dual champion of domestic R&D with Huawei?"
"Thirty years east of the river, thirty years west of the river, fortunes change, this year it's the pharmaceutical industry's turn, and our biochemistry, environmental science, and materials science institute is destined for great success!"
Leaving aside the excitement and agitation of netizens, the eagerness and envy in the financial sector, and the blushing faces of domestic pharmaceutical company executives upon seeing Three Purities's statement, they all turned their heads away, pretending not to see it.
"That's just how things are in our country, there's nothing we can do about it," they thought.
An individual's inertia can be frighteningly stubborn, let alone the inertia of an industry.
Although Three Purities is striving to go against the trend, it is not yet time to turn the tide for the entire industry.
Just as industry insiders remained silent on the matter, a post suddenly appeared online. "A startling observation of the astonishing amount of R&D investment in China's pharmaceutical industry based on the statement from Three Purities!"
The poster was Chang Sanwei, the Jingda Biology Department, a renowned biological scientist, and an academician of the Chinese Academy of Sciences. He is well-known online for his outspokenness and often criticizes various unfair or bizarre situations in the industry, hence the nickname "Chang Duìduì".
The post provided a detailed analysis of the R&D investment of major domestic pharmaceutical companies and praised Three Purities's emphasis on R&D, which immediately sparked heated discussions across the internet.
"At this moment, a phenomenon that can be described as 'astonishing in China's has emerged in the domestic pharmaceutical industry."
"The most profitable and highest-revenue pharmaceutical company in the industry does not go public or seek financing. Instead, it quietly spends all its profits on drug research and development and basic scientific research. One company supports an entire industry."
"But listed pharmaceutical companies are forging their own path, which is full of China characteristics."
Data shows that the total R&D expenditure of 373 listed pharmaceutical companies last year was only 61.3 billion yuan, which is less than that of multinational pharmaceutical company Roche alone.
Take Hengrui, a leading pharmaceutical company, as an example. Last year, its R&D expenditure ranked outside the top 40 among global pharmaceutical companies. If all sales expenses were used for R&D, the total R&D expenditure would be approximately $1.9 billion, which would significantly improve its ranking to around 20th, putting it on par with mid-sized pharmaceutical companies like Novo Nordisk.
Domestic pharmaceutical companies have made a fortune in the past two years. Where exactly did they spend their money?
The answer is marketing and promotion.
Last year, a total of 373 listed companies released their performance reports, with total revenue of 1.92 trillion yuan and net profit of 135.1 billion yuan. Sales expenses reached 279 billion yuan, of which 67.2 billion yuan was for sales staff salaries, and the remaining 211.8 billion yuan was mainly used for promotion, including academic promotion, entertainment expenses, conference fees, publicity expenses, and travel expenses.
Take Hengrui Medicine as another example. Last year, the company's total revenue was 27.7 billion yuan, and its net profit was 6.3 billion yuan. However, its total sales expenses for the year were 9.8 billion yuan, of which 4.2 billion yuan was used for marketing expenses such as academic promotion and the construction of a professional platform for innovative drugs.
You reap what you sow; with such low investment, the entire industry is naturally rife with hype. Don't be Smallpox by the dazzling presentations of various innovative drug companies; in reality, 90% of new drug projects in China are derivatives developed targeting targets that have already been validated both domestically and internationally.
Although derivative drugs are modeled after the original drugs, they are all derivative drugs in a strict sense if their chemical structure is slightly modified.
Foreign new drugs are all original research drugs, which are the first or best in their class. The development cost of new drugs is between 1 billion and 2.2 billion US dollars, and the success rate from entering clinical trials to obtaining new drug approval is 9.6%. In contrast, the development cost of domestic derivative new drugs is less than 100 million US dollars, and the success rate from clinical trials to obtaining new drug approval is as high as 80%.
This knock-off-style new drug strategy looks appealing, but it also means lower profit prospects and increased business competition.
So, are there any highlights in my country's pharmaceutical industry that allow it to be in a leading position in the world?
Yes, of course.
That is—its valuation is absolutely the highest in the world.
In terms of market size, China's pharmaceutical market is currently worth about 800 billion yuan, while that of the Eagle Country is about four times that of China. The global pharmaceutical market is worth 1.2 trillion US dollars, which is about nine times that of China.
From the perspective of corporate strength, foreign pharmaceutical companies that have the latest and best truly new drug products in the same category have high R&D investment and high revenue and profits, but their market value is lower than that of a domestic pharmaceutical company that only has derivative products in the domestic market.
Doesn't this seem ridiculous and laughable?
Isn't this something that will amaze the China?
Haha, you could say that domestic new drug companies are currently working with the mindset of selling cabbages, but are being valued at the lowest possible price.
In any case, one must be strong to achieve results. To produce results, one needs not only solid strength but also substantial financial investment in scientific research.
This industry needs to learn from Three Purities famous Chinese pharmaceutical company), calm down, and cultivate its internal strengths to keep up with the leaders and avoid falling behind. Otherwise, it will likely face a brutal cleansing and reshuffling, leaving only a mess after the market competition. How many companies will be able to stand firm?
Netizens were immediately amazed and full of admiration after seeing it.
"Three Purities is indeed a breath of fresh air in the industry."
"This person is definitely an insider; they see things clearly. Reform in this industry is imperative."
"To be honest, I would rather the entire industry be left with only Three Purities than pay money to take medicine from these useless pharmaceutical companies."
"So that's how it is. Now I finally understand where all the bizarre phenomena in the pharmaceutical industry come from."
"No wonder drug prices are getting higher and higher, but the truly effective drugs still have to be imported. It turns out that these bastards have used them all for marketing."
"My goodness, Chang Duìduì is really good at criticizing academicians. He's probably going to offend a lot of people now."
"They're academicians, what's there to be afraid of? Our country needs experts like them to speak out so that the industry can move forward."
"This is a real expert! Dui Dui is really great, I love him!"
"I hope Three Purities can play a leading role in the industry, or at least let other pharmaceutical companies follow suit."
"I think it's difficult. If you can make quick money, why would you want to make money through slow and difficult research and development?"
This proclamation also reached Wei Kang's ears. He read it carefully and sighed, "No one understands me better than you."
This post really resonated with him, and the other party also praised the Three Purities highly.
That means we must express our support.
Wei Kang acted quickly, immediately contacting Academician Chang through Academician Qi Academician Chang inviting him to become an honorary advisor to Three Purities.
The two sides hit it off immediately, and Three Purities took the opportunity to propose a strategic cooperation between the university and the Jingda Biology Department.
Three Purities is now rich and famous, but what it lacks most is cutting-edge scientific research capabilities and outstanding talents in the industry.
Wei Kang looked at the talented people from Peking University with great envy. In the past, most of these people would go abroad to study and then never come back.
Three Purities has now made a name for itself among global pharmaceutical companies, which will likely increase its attractiveness to these high-level talents.
After all, who wouldn't want to return home in glory after completing their studies?
Previously, no domestic pharmaceutical companies were willing to spend money on scientific research. Now, there are companies like Three Purities.
It is believed that a large wave of overseas talent will return.
Three Purities also aims to build the world's leading biochemical research and development base.